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African horse sickness virus (AHSV) causes a fatal disease in horses. The virus capsid is composed of a double protein
layer, the outermost of which is formed by two proteins: VP2 and VP5. VP2 is known to determine the serotype of the virus
and to contain the neutralizing epitopes. The biological function of VP5, the other component of the capsid, is unknown. In
this report, AHSV VP5, expressed in insect cells alone or together with VP2, was able to induce AHSV-specific neutralizing
antibodies. Moreover, two VP5-specific monoclonal antibodies (MAbs) that were able to neutralize the virus in a plaque
reduction assay were generated. To dissect the antigenic structure of AHSV VP5, the protein was cloned in Escherichia coli
using the pET3 system. The immunoreactivity of both MAbs, and horse and rabbit polyclonal antisera, with 17 overlapping
fragments from VP5 was analyzed. The most immunodominant region was found in the N-terminal 330 residues of VP5,
defining two antigenic regions, I (residues 151–200) and II (residues 83–120). The epitopes were further defined by PEPSCAN
analysis with 12mer peptides, which determined eight antigenic sites in the N-terminal half of the molecule. Neutralizing
epitopes were defined at positions 85–92 (PDPLSPGE) for MAb 10AE12 and at 179–185 (EEDLRTR) for MAb 10AC6. Epitope
10AE12 is highly conserved between the different orbiviruses. MAb 10AE12 was able to recognize bluetongue virus VP5 and
epizootic hemorrhagic disease virus VP5 by several techniques. These data will be especially useful for vaccine development
and diagnostic purposes. © 1999 Academic Press(
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CINTRODUCTION
African horse sickness virus (AHSV) is an arthropod-
orne orbivirus of the family Reoviridae and is the causal
gent of African horse sickness (HAS), characterized by
high mortality in horses and other equids. To date, nine
erologically distinct AHSV serotypes (AHSV-1 to
HSV-9) have been identified with no evident cross-
eutralization among them. The disease is confined to
ub-Saharan Africa, although periodic epizootics have
aused severe outbreaks of the disease outside enzootic
egions, i.e., North Africa, the Middle East, and southern
urope (Rodriguez et al., 1992; Mellor, 1993). AHSV viri-
ns possess a double-stranded RNA genome of 10 dis-
rete segments, each encoding one to two proteins (Roy
t al., 1994), encapsidated by two distinct protein shells.
he outer layer of the virus is composed of two proteins,
P2 and VP5, whereas the inner capsid is formed by two
ajor polypeptide chains, VP3 and VP7, enclosing three
ther minor proteins, VP1, VP4, and VP6.
AHSV-4 VP5 is a 56-kDa protein, rich in nonpolar
mino acids (Iwata et al., 1992). The bluetongue virus
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 1 34914087598. E-mail: icasal@ingenasa.es..449BTV) VP5 has a globular structure (Hewat et al., 1992).
ang and Li (1993) reported N-linked glycosylation of BTV
P5; however, it has been shown that AHSV-9 VP5 is not
-linked glycosylated (du Plessis and Nel, 1997). Al-
hough present in the outer shell of the virus particles,
P5 is mostly unexposed on the surface of the virus.
espite this, it is one of the earliest serologic markers in
HSV infections (Martinez-Torrecuadrada et al., 1997). Its
iological function remains unknown. Orbivirus VP5 pro-
eins are relatively conserved, with 45% identity between
HSV-4 and BTV-10 and 43% identity between AHSV-4
nd epizootic hemorrhagic disease virus-1 (EHDV-1),
ith identity rising to 64% when amino acids of similar
haracter are considered (Roy et al., 1994). If VP5 se-
uences from different AHSV serotypes are compared,
0% of the amino acids are similar, of which 81% are
dentical, between AHSV-4 VP5 and AHSV-9 VP5 (du
lessis and Nel, 1997), and 91% of similar amino acids
nd 83% of identical amino acids are shared between
HSV-4 and -6 VP5 (Williams et al., 1998).
It has been shown that AHSV capsid protein VP2
licits serotype-specific antibodies (Bremer et al., 1990)
nd is a major target for the neutralizing response of the
ost (Ranz et al., 1992; Burrage et al., 1993; Martı´nez-
orrecuadrada et al., 1994; Martı´nez-Torrecuadrada and
asal, 1995). The presence of neutralizing epitopes ex-0042-6822/99 $30.00
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450 MARTI´NEZ-TORRECUADRADA ET AL.lusively on VP2 has also been well established in other
embers of orbivirus genus, such as BTV (Huismans
nd Erasmus, 1981; Grubman et al., 1983; Marshall and
oy, 1990) and Palyam serogroup viruses (Whistler and
wanepoel, 1990), except for Kemerovo serogroup vi-
uses like Broadhaven virus (BRDV), in which the
pitopes responsible for neutralization were located on
he corresponding VP5 protein (Moss et al., 1987). How-
ver, it has not been described previously that both
roteins of the outer capsid of an orbivirus contain
pitopes responsible for virus neutralization. The role of
P5 in neutralization has not yet been clearly assigned.
revious results have shown that the presence of VP5
ogether with VP2 in BTV and AHSV can enhance the
mmune response, despite the fact that antibodies raised
gainst purified or recombinant BTV VP5 alone do not
eutralize BTV infectivity (Marshall and Roy, 1990; Roy et
l., 1990). Recently, we have shown that the best confor-
FIG. 1. Schematic representation of AHSV-4 VP5 fragments. The fra
ppropriate restriction enzymes sites or PCR. The VP5 gene is represe
rimers for PCR are shown as small bars with the corresponding nam
ndicated above each fragment.ation of VP2 to expose the immunodominant neutral-
zation epitopes was achieved when coexpressed with
P5 in the baculovirus system. Moreover, the use of
hese proteins together with VP7 induced a complete
rotective immune response in horses (Martı´nez-Torrec-
adrada et al., 1996). Current AHS vaccines contain mod-
fied live virus or inactivated virus. Although these vac-
ines are quite protective, their use can present some
isadvantages, such as possible reversion to virulence
y mutation or genome segment reassortment with cir-
ulating virus, incomplete attenuation or inactivation, the
equirement of handling large amounts of live virus, and
he difficulty in distinguishing vaccinated and infected
nimals. Therefore, the development of a noninfectious,
afe subunit virus vaccine would be of fundamental im-
ortance.
The mapping of antigenic determinants, especially
eutralizing epitopes, is essential in order to learn more
were constructed as described under Materials and Methods using
y a darker line showing the restriction enzyme sites in italics and the
d in the fragmentation process. Fragment names and sizes (bp) aregments
nted b
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451ANTIGENIC STRUCTURE OF AHSV-4 VP5bout virus neutralization and to identify the critical
pitopes required for the development of a subunit or
ynthetic vaccine and diagnostic reagents. In this report,
e have used a collection of recombinant proteins and
ynthetic peptides to delineate eight antigenic sites on
P5 of AHSV-4. These were determined by analyzing
eutralizing antibody samples from different sources
monoclonal antibodies (MAbs) and horse and rabbit
olyclonal antisera) for their affinity to recombinant frag-
ents and synthetic peptides of AHSV-4 VP5 (see Fig. 1).
RESULTS
frican horse sickness virus neutralization
nduced by VP5
To investigate the immunogenicity of the baculovirus-
xpressed AHSV-4 VP5 and to determine whether or not
HSV-4 VP5 is able to elicit antibodies that neutralize
omologous virus, rabbits were immunized with baculo-
irus-infected cell extracts containing recombinant VP5.
ntibodies to recombinant VP5 reacted with the virion by
LISA, reaching titers higher than 104. Likewise, by West-
rn blot analysis the anti-VP5 serum was shown to give
FIG. 2. Recognition in Western blot analyses of virion VP5 by AHSV-4
P5-specific MAbs and rabbit anti-VP5 serum. Proteins from purified
HSV-4 were separated on SDS–9% polyacrylamide gel, transferred
nto a nitrocellulose membrane, and cut into strips. The strips were
ncubated with the corresponding MAb or rabbit serum as indicated on
he top of each strip, and reaction was detected using phosphatase-
onjugated anti-mouse or protein A for rabbit immunoglobulins using
BT and BCIP as substrates. The migrations of VP5 and truncated
orms are indicated as VP5 on the right-hand side.ositive signals with viral VP5 and truncated forms of
P5, albeit at low levels as shown in Fig. 2.
The ability of the rabbit anti-VP5 serum to neutralize
HSV-4 in vitro was determined by a monolayer protec-
ion assay in the absence of complement (Table 1). VP5
as able to induce neutralizing antibodies at titers of 102.
abbit anti-VP2 serum and AHSV-4 infected horse serum
sed as positive controls showed titers of 103 and 104,
espectively. As expected, the preimmune rabbit serum
id not contain any AHSV-4 neutralizing activity. These
ata confirm that VP5 contains neutralizing epitopes for
HSV and can elicit a significant neutralizing response
lbeit at titers that were significantly lower than those
nduced by VP2.
roduction of AHSV VP5-specific monoclonal
ntibodies
After seven fusions only two MAbs (10AC6 and
0AE12) that were positive to VP5 by ELISA and immu-
oblotting (Fig. 2) were produced. However, both failed to
mmunoprecipitate VP5 (data not shown). The character-
stics of the two MAbs are summarized in Table 2. MAb
0AC6 was IgG2a, whereas 10AE12 was IgG1. A com-
etitive binding ELISA was developed in order to deter-
ine whether 10AC6 and 10AE12 react with distinct an-
igenic sites. 10AC6 and 10AE12 did not compete for
ntigen binding, suggesting that they recognize different
pitopes and therefore define two antigenic sites on VP5,
urther discussed as sites I and II. These results sug-
ested that epitopes recognized by both MAbs would be
inear and might become exposed after denaturing con-
itions.
The functional relevance of the epitopes recognized by
oth MAbs 10AC6 and 10AE12 was tested in vitro by a
laque reduction assay. Surprisingly both MAbs exhib-
ted neutralizing activity; MAb 10AE12 was able to reduce
he plaque-forming units (PFU) number of AHSV-4 up to
0%, and MAb 10AC6 was able to reduce it to a some-
hat lesser extent (Table 2). Ascitic fluid of a highly
eutralizing AHSV-4 VP2-specific MAb, 8CH7, was used
TABLE 1
Neutralization Activity Elicited by VP5
Serum Neutralization titera
Rabbit a-VP5 256
Rabbit a-VP2 1,280
Horse a-AHSV-4 10,240
Rabbit prea-VP5 ,5
a Neutralization titers represent the reciprocal of the highest serum
ilution that causes 50% reduction in plaque-forming units, in a Vero
onolayer protection assay. Sera from rabbits immunized with recom-
inant VP2 and an experimentally infected horse were included as
ositive controls. Preimmune rabbit serum was used as negative con-
rol. Sera were inactivated for 30 min at 56°C to remove complement.
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452 MARTI´NEZ-TORRECUADRADA ET AL.s a positive control and reduced the viral infectivity by
ore than 98%. A negative control did not neutralize.
xpression of recombinant VP5 fragments in
scherichia coli
The AHSV-4 VP5 gene and 17 overlapping fragments
f the VP5 protein were cloned in pET3- or pET3x-derived
ectors, which were designated pET3b-VP5, pET3b-DA,
ET3c-DB, pET3b-DC, pET3xb-DD, pET3xa-DE, pET3xb-
F, pET3xa-DG, pET3xb-DH, pET3xb-DI, pET3xa-DJ,
ET3xa-DK, pET3xa-DL, pET3xa-DM, pET3xb-DN,
ET3xb-DO, pET3xc-DP, and pET3xa-DQ. After a 3-h in-
uction, the corresponding recombinant proteins gener-
ted were analyzed by Coomassie blue staining of SDS–
AGE (Fig. 3). It was remarkable that all the fragments
ontaining the amino terminus of the molecule (pET3b-
P5, pET3b-DA, and pET3xb-DD) were extremely toxic to
. coli, causing a significant decrease in the growth rate
f the cells and leading to rapid cell lysis after induction
ith 0.4 mM IPTG. These plasmids were viable only in
he presence of pLysE, resulting in a very low level of
xpressed fragment, since cells carrying this plasmid
ccumulate substantial levels of lysozyme that reduce
he basal level of T7 RNA polymerase.
Fragments that did not contain the VP5 amino termi-
us were expressed at high levels in the bacterial cells
s shown in Fig. 3. In most cases, a band was observed
ith a size in agreement with the expected molecular
ass according to the coding capacities of the ex-
ressed fragment. Fragments J and P migrate abnor-
ally. This artifact could be explained by a high propor-
ion of charged residues in these fragments (Takano et
l., 1988). Although the fusion proteins were insoluble,
arge quantities could be readily enriched and partially
urified by solubilization with 4 M guanidinium hydro-
hloride.
pitope mapping with recombinant VP5 fragments
The location of antigenic epitopes was determined in
he different E. coli-derived VP5 fragments by immuno-
lotting analyses with MAbs and antisera from infected
orses and immunized rabbits (Table 3). As expected,
he whole VP5 was recognized by all the antibodies
sed. VP5 was initially divided into fragments A and B.
T
Summary of AHSV-4
Hybridoma Isotype
Antigenic
site I
10AC6 IgG2a I —
10AE12 IgG1 II —
a ELISA titers were expressed as the concentration of purified IgG g
b Neutralizing activity was measured as the percentage of inhibitionragment A was expressed at very low levels, making it
ifficult to assess its reactivity with antibodies. Fragment
was extensively synthesized; however, it did not react
ith the MAbs or the antisera, indicating a very low
ntigenicity. Therefore, epitope mapping was focused on
he larger part of the molecule. Fragment A was divided
n three portions, C, D, and E. Fragment C reacted with
Ab 10AC6, with horse antisera, and slightly with the
nti-VP2VP5 rabbit sera. Fragment D, which contains the
-terminus of the protein, was clearly recognized by
orse and rabbit anti-VP2VP5 sera, despite its low ex-
Ab Characterization
Western
blot
ELISA
titera Neutralizationb
111 0.1 mg/ml 68%
111 0.1 ng/ml 80%
ree times the blank value.
l infectivity in a plaque-forming units reduction test.
FIG. 3. SDS–PAGE analysis of the expression of the AHSV-4 VP5
ragments in E. coli (strains BL21(DE3)pLysS or BL21(DE3)pLysE). Bac-
eria containing the recombinant pET3- or pET3x-derived plasmids
ere induced for 3 h with 0.4 mM IPTG. After treatment with loading
uffer and boiling for 5 min, proteins were separated on a 7–15%
DS–polyacrylamide gel and stained with Coomassie blue. Each line
epresents bacterial lysates transformed with the following expression
ectors: lane 1, pET3b-VP5; lane 2, pET3b-DA; lane 3, pET3c-DB, lane 4,
ET3c-DC; lane 5, pET3xb-DD; lane 6, pET3xa-DE; lane 7, pET3xb-DF;
ane 8, pET3xa-DG; lane 9, pET3xb-DH; lane 10, pET3xb-DI; lane 11,
ET3xa-DJ; lane 12, pET3xa-DK; lane 13, pET3xa-DL; lane 14, pET3xa-
M; lane 15, pET3xb-DN; lane 16, pET3xb-DO; lane 17, pET3xc-DP; lane
8, pET3xa-DQ. Molecular weight markers (M) are given in kDa on the
eft-hand side. Positions of fusion proteins are indicated with arrow-
eads.ABLE 2
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453ANTIGENIC STRUCTURE OF AHSV-4 VP5ression. No MAb gave a positive reaction with this
ragment. Finally, fragment E reacted strongly with horse
ntisera, rabbit anti-VP2VP5 sera, and MAb 10AE12. To
urther define the epitopes, regions C and E were divided
n two segments each: F and G, and N and O, respec-
ively. Polyclonal antisera reacted intensely with frag-
ents F, N, and O and, to a lesser extent, with fragment
. MAb 10AC6 reacted exclusively with fragment F and
Ab 10AE12 recognized fragment O.
To further locate the epitope defined by MAb 10AC6,
ragment F was split into two halves, H and I, through the
luI restriction site present at nt 616. Only fragment H
49 aa) was recognized by MAb 10AC6. Four overlapping
olypeptides covering the length of fragment H were
hen expressed in E. coli, resulting in fragments J, K, L,
nd M. Surprisingly, none of these fragments were able
o react with 10AC6. These fragments were also tested
ith the polyclonal sera. Horse sera reacted with frag-
ents H, I, and M and rabbit anti-VP2VP5 sera recog-
ized fragments H, I, and J.
To define the 10AE12 epitope, two polypeptides in-
luded in fragment O were also constructed, yielding
ragments P and Q. MAb 10AE12 recognized fragment P,
ut not Q. Fragment P also gave a stronger reaction to
olyclonal sera than did fragment Q.
In summary, two major antigenic domains correspond-
ng to fragments E and F were identified on the N termi-
us of VP5. By successive fragmentation of these re-
ions and expression in E. coli, the antigenic site I,
TABLE 3
Reactivity of VP5 Fragments by Immunoblotting
with Horse and Rabbit Antisera
Fragment
Amino
acids
Mab
10AC6
Mab
10AE12
Horse
a-AHSV-4
Rabbit
a-VP2VP5
VP5 1–505 111 111 11a 11
Ab 1–341 1 1 2 1
B 341–505 2 2 2 2
C 151–341 111 2 11 1
Db 1–49 2 2 1 1
E 48–150 2 111 111 111
F 151–265 111 2 111 111
G 264–341 2 2 1 11
H 151–200 111 2 111 111
I 200–265 2 2 111 11
J 174–189 2 2 2 11
K 151–174 2 2 2 2
L 151–189 2 2 2 2
M 174–200 2 2 1 2
N 21–84 2 2 111 111
O 85–150 2 111 111 111
P 83–120 2 111 11 11
Q 121–150 2 2 1 1
a 2, no reaction; 1, positive reaction (from 111, maximum to 1,
light reaction).
b Extremely low expression of these fragments due to toxicity for
acteria.ecognized by MAb 10AC6, was located between aa 151
nd 200, and the antigenic site II, defined by MAb
0AE12, was situated between aa 83 and 120.
mmunogenicity of VP5-derived fragments
In an attempt to investigate whether or not E. coli-
erived fragments, comprising the neutralizing domains I
nd II, were able to elicit neutralizing antibodies, mice
ere immunized with purified fragments E and H, con-
aining 10AE12 and 10AC6 epitopes, respectively. After
he mice were immunized three times, serum samples
ere tested for their ability to neutralize the virus in vitro
y a monolayer protection assay. However, none of the
era showed any detectable neutralization activity, de-
pite the fact that they were able to react with the
HSV-4 virion by ELISA and with the corresponding pep-
ides by PEPSCAN analyses (data not shown).
pitope mapping with synthetic peptides
PEPSCAN analysis of the VP5 sequence was used to
efine linear antigenic domains and thus to delineate
ore precisely the binding specificity of MAbs 10AE12
nd 10AC6, rabbit antisera to recombinant AHSV4 VP5
nd VP2/VP5, or horse antisera to AHSV-4. Eight anti-
enic sites were identified with the rabbit antisera and
he two MAbs. They were numbered 1 through 8, accord-
ng to their order of occurrence from the N-terminus (Fig.
). The amino acid sequences corresponding to the pep-
ides involved in these sites are displayed in Table 4.
onsidering the height of the absorbances at the anti-
enic sites, the MAbs exhibited higher avidity than the
abbit sera, and rabbit antiserum to VP2/VP5 was of
igher titer than rabbit anti-VP5 serum. Some antibody
amples share the same antigenic sites: site 4 for MAb
0AE12 and rabbit anti-VP2/VP5; site 6 for rabbit sera to
P5 and to VP2/VP5. Sites 1, 3, 4, 6, 7, and 8 detected by
EPSCAN with rabbit antiserum to VP2/VP5 agreed quite
ell with the reactivity of the recombinant fragments in
estern blot analysis (Tables 3 and 4), especially the
egions between residues 27 and 98 (sites 1, 3, and 4)
nd between 211 and 232 (site 7), which are most anti-
enic. The equine sera did not exhibit any binding to the
eptides.
The surface accessibility of these sites on the virus
as studied by blocking antibody binding with purified
HSV-4. Whereas no surface exposure of the mapped
inear antigenic sites could be shown for the two MAbs,
he binding by rabbit polyclonal antibodies to antigenic
ites 2, 3, 4, 6, 7, and 8 could be blocked by more than
0% with respect to a control absorption with an irrele-
ant virus. Surprisingly, binding to antigenic site 4 could
e blocked using rabbit antiVP2/VP5 serum, but hardly at
ll using the MAb 10AE12. This suggests that the MAb
as a greater affinity to the linear sequences displayed
y the synthetic peptides than by the virus, suggesting
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454 MARTI´NEZ-TORRECUADRADA ET AL.hat the recognition site of MAb 10AE12 at the epitope
evel is not fully exposed on the surface of the virus. In
ontrast, the polyclonal rabbit antiVP2/VP5 serum has a
reater affinity for the intact virus. These results indicate
hat the epitopes recognized by the MAb and the poly-
lonal antisera, although identical at the amino acid
equence level must be different at the atomic level,
hich defines the epitope–paratope interaction (Van Re-
enmortel, 1998). Nevertheless, the blocking of antibody
inding by native protein or virus as shown in these
xperiments is indicative of surface exposure.
onservation and cross-reactivity of epitopes
etween orbiviruses
The conserved nature of the antigenic sites that bind
o MAbs 10AE12 and 10AC6 was studied between the
iral family members AHSV, BTV, EHDV, and BRDV. Align-
ent of cognate VP5 sequences showed that MAb
0AE12 recognizes a highly conserved epitope in orbivi-
uses (Fig. 5). The sequence of site II, or antigenic site 4
ccording to the PEPSCAN data, PDPLSPGE is present
FIG. 4. Mapping of antigenic sites with 12-mer peptides using PE
umbered 1–8, from N- to C-terminus. a–d represent the results obtain
era. The sequences involved in these antigenic sites are displayed inn all the VP5 sequences from different serotypes of BTV
nd EHDV. There is only a single substitution in AHSV-9
P5, Ser88 3 Asn. However, this is a conservative
hange since both amino acids are polar. BRDV VP5,
hich is more distantly related, showed two substitu-
ions, Ser88 3 Asn and Gly90 3 Val. On the other hand,
or the 10AC6 epitope, only two of seven amino acids are
onserved among the orbiviruses analyzed. These re-
ults were confirmed by Western blot analysis, since
Ab 10AE12 was able to recognize baculovirus-derived
P5 from BTV-10 and EHDV-1 (Fig. 6), while MAb 10AC6
eacted only with AHSV-4 VP5 (data not shown).
DISCUSSION
VP5 is a protein present in the outer shell of the
rbivirus particle (Roy, 1992), whose biological role re-
ains to be clarified. To date, it has been assumed that
ntibodies against orbivirus VP5 do not neutralize infec-
ivity (Mertens et al., 1989; Roy et al., 1990; Marshall and
oy, 1990). This does not seem to be true for AHSV, as we
ave demonstrated here that recombinant VP5 ex-
analysis. Antigenic sites detected in four antibody samples were
g MAb 10AE12, MAb 10AC6, rabbit anti-VP5, and rabbit anti-VP5/VP2
4.PSCAN
ed usin
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455ANTIGENIC STRUCTURE OF AHSV-4 VP5ressed in insect cells and used for rabbit immunization
as able to elicit a significant neutralizing activity. More-
ver, two mouse MAbs obtained after immunization with
irions were also able to neutralize AHSV and their
inding specificity was mapped to the small peptide
evel. This is the first report of such neutralizing ability
ssociated with an orbivirus VP5. Since no three-dimen-
ional structure is currently known for AHSV, correlations
f antigenic differences between AHSV and BTV and the
tructure of their outer capsid proteins cannot be deter-
ined. It is likely that structural differences between the
wo viruses may account for some of the differences in
mmunological behavior.
T
Antigenic Sites Identified
Sitea Antibody Se
1 Rabbit aVP2/VP5 MYKLAGKTL
2 Rabbit aVP5 DGVMQGAI
3 Rabbit aVP2/VP5 KQAVILNVA
4 10AE12 LESAPDPLS
4 Rabbit aVP2/VP5 PDPLSPGEQ
5 10AC6 RALQTEEDL
6 Rabbit aVP2/VP5 EYREKFDAL
6 Rabbit aVP5 YREKEDALK
7 Rabbit aVP2/VP5 ATHDEAIQE
8 Rabbit aVP2/VP5 TQHVIDAVL
a Site numbers correspond to those assigned in Fig. 4.
b The complete peptide sequence of an antigenic site is given. The
eptides of that antigenic site.
c Blocking of antibody binding by purified AHSV-4 was calculated a
ethods. The control samples with the ADV material yielded compara
FIG. 5. Alignment of the amino acid sequences of VP5 from different
rbiviruses between residues 85 and 92 and residues 179 and 185
orresponding to epitopes recognized by MAbs 10AE12 and 10AC6,
espectively. The sequences of the orbivirus VP5s are available from
he GenBank database under the following accession numbers:
HSV-4 VP5, M94731; AHSV-6 VP5, AF021237; AHSV-9 VP5, U74489;
TV-1S VP5, M36713; BTV-2A VP5, X62283; BTV-10 VP5, D12532;
TV-11 VP5, U03284; BTV-13 VP5, X54308; BTV-17 VP5, X55359; EHDV-1
P5, X55782, and BRDV VP5, M58030. The conserved amino acids are
ndicated by asterisks.The antigenicity of the capsid protein VP5 of AHSV
erotype 4 appears to be mostly located in its N-terminal
30 residues and more specifically inside fragments E
nd F, spanning residues 48–265. In fact, when the an-
igenicity was mapped at the peptide level, most of the
ight linear antigenic sites defined by PEPSCAN (sites 2
o 7) were mapped in this area of the VP5. Antigenic sites
n AHSV VP5 were defined by using mouse MAbs and
abbit antisera. The use of horse sera did not allow the
PSCAN on AHSV-4 VP5
b
Position in
VP5
% Blocking
by AHSV-4c
SEVG 27–44 38
E 49–63 100
P 70–85 64
LYNKV 81–99 8
85–98 93
TRM 174–190 0
E 193–208 65
194–206 27
AEVIETAS 211–232 86
315–327 96
ined amino acids represent the common sequence present in all the
centage as described under the PEPSCAN section of Materials and
k heights as in the untreated samples analyzed in Fig. 4.
FIG. 6. Reactivity of MAb 10AE12 with orbivirus VP5s by Western blot.
rude extracts of Sf9 cells infected with recombinant baculoviruses
cAHSV-4.5, AcEHDV-1.5, or AcBTV-10.5 expressing AHSV-4 VP5,
HDV-1 VP5, and BTV-10 VP5, respectively, were prepared, mixed with
rotein sample buffer, and loaded onto a 9% SDS–polyacrylamide gel.
ractionated proteins were transferred to a nitrocellulose filter and
ncubated with MAb 10AE12 as described under Materials and Meth-
ds. The arrow indicates the migration of the recombinant orbivirus
P5s. Molecular weight markers are indicated on the left-hand side.ABLE 4
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456 MARTI´NEZ-TORRECUADRADA ET AL.haracterization of any antigenic site in VP5 at the amino
cid level, although immunoblotting reactivity with the
ragments did define the same immunodominant re-
ions E and F and several subareas inside these two.
he absence of detecting binding of horse sera to VP5
eptides is a puzzling observation. The most likely ex-
lanation is that the length of the epitopes recognized by
he horse sera is longer than the 12-mers used in the
EPSCAN analysis. In fact, recent data in our laboratory
upport this hypothesis, as horse sera were able to
ecognize a 18-mer peptide based on the 10AE12 epitope
VP5 residues 81–99) in an indirect ELISA (Martı´nez-
orrecuadrada, unpublished results). This is one of the
imitations of the PEPSCAN technology, which has been
hown previously for other epitopes (Kusters et al., 1989).
hese results suggest that horse antibodies mainly rec-
gnize longer linear epitopes or discontinuous epitopes
esulting from a combination of sequences from different
roteins (VP2, VP5, and/or VP7).
Antigenic site 4, defined by MAb 10AE12, has several
nteresting properties: (i) it is able to induce neutralizing
ntibodies; (ii) it is well conserved, not only among the
HSV serotypes, but also among the different orbiviruses
BTV, EHDV, BRDV); and (iii) antibodies to this site are
ble to recognize VP5 proteins from BTV and EHDV by
mmunoblotting, which suggests that MAb 10AE12 can
e used as a group-specific reagent, suitable for the
etection of any orbivirus infection. This is the first report
f such a reagent for use with orbiviruses. Further de-
elopment of this MAb, and the corresponding synthetic
eptide, for diagnostic applications is under investiga-
ion.
However, antisera from mice immunized with fragment
, which contains the 10AE12 epitope, were unable to
eutralize the virus. The conserved sequence probably
eflects the lack of exposure of the epitope on the virus
urface and, probably, an important structural role for this
equence. The lack of exposure was confirmed by the
ailure of this MAb to immunoprecipitate VP5 and by the
bsorption experiments with full virions in PEPSCAN.
ince the MAbs were generated by immunization with
ntact AHSV-4 virions, this site must have become ex-
osed during denaturation, disassembly, and/or pro-
essing of the virus in the target animal. However, MAb
0AE12 is able to bind to VP5 on purified AHSV-4 in an
LISA assay (Table 2), suggesting that the correspond-
ng epitope is not deeply buried, because the small
onformational changes induced in the particles when
oated on ELISA plates are enough to improve its ac-
essibility.
BTV VP5 epitope mapping (Wade-Evans et al., 1988;
ang et al., 1992; Wang et al., 1995) described several
ntigenic determinants also located in the N-terminal
alf of the molecule. One of these was a linear epitope
ocated between residues 175 and 189 (Yang et al., 1992),
hich corresponds very closely with site 5 defined byAb 10AC6 in AHSV. Another group has identified the
egion bound by the BTV-specific MAb 30F12, using
hage display, between residues 142 and 183 (Wang et
l., 1995). The antigenic region (aa 175–189) described by
ang et al. (1992) seems to be exposed on the surface of
he virion in five US BTV serotypes, which appears con-
radictory to our results regarding the accessibility of the
pitope for 10AC6. This could be due to minor variations
n the surfaces of both orbiviruses. In any case, it is clear
hat this region is a hot immunogenic spot in the VP5 of
rbiviruses. The amino acid sequence at this region is
ell conserved among BTV serotypes, but very poorly
onserved between orbiviruses (Fig. 5). It also corre-
ponds to a very hydrophilic region of the VP5 in both
TV and AHSV. Surprisingly, MAb 10AC6, which recog-
izes this epitope, was found to be weakly neutralizing.
n contrast, antisera from mice immunized with E. coli-
erived fragments containing the epitope did not show
etectable neutralizing titer, although they reacted
trongly with the peptide as demonstrated by PEPSCAN
nalysis (data not shown).
No antigenic regions were found in the C-terminal part
f VP5, as no antibodies of any origin, including horse,
eact with this region. Sequence comparisons with BTV,
HDV, and BRDV showed that this region is relatively
ell conserved among the different orbiviruses, suggest-
ng that it is probably not exposed and may be involved
n the preservation of the virus structure. A similar situ-
tion was described for AHSV-4 VP2 (Martı´nez-Torrec-
adrada and Casal, 1995). We can thus speculate that
he C-terminal regions of both proteins are interacting to
upport the outer shell structure, but are inaccessible to
he immune system.
In conclusion, an immunodominant region, between
esidues 48 and 265, and eight different antigenic sites
ave been mapped in the AHSV-4 VP5. The N terminus of
P5 seems to be the most immunodominant region and
ay be the most surface-exposed and accessible to
ntibodies area in VP5. In contrast to the VP5 proteins
rom other orbiviruses, AHSV VP5 alone is able to induce
eutralizing antibodies albeit at lower levels than VP2.
ince the defined epitopes are bound by neutralizing
Abs and one of them is conserved among different
rbiviruses, the amino-terminal region of VP5 could be of
pecial interest for inclusion in a new generation of
accines for AHSV and diagnostic tests for orbiviruses.
MATERIALS AND METHODS
ells and viruses
AHSV-4 was grown and assayed in confluent mono-
ayers of a permanent line of Vero cells (ATCC CCL 81) in
ulbecco’s modified Eagle’s medium (Gibco BRL) sup-
lemented with 5% fetal calf serum (FCS) and antibiotics.
HSV virions were purified as described previously
Martı´nez-Torrecuadrada et al., 1994). The Spodoptera
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457ANTIGENIC STRUCTURE OF AHSV-4 VP5rugiperda cell clone Sf9 (ATCC CRL1711) was used to
ropagate recombinant baculovirus AcAHSV-4.5 and to
xpress AHSV-4 VP5 (Martı´nez-Torrecuadrada et al.,
994). Also, AcBTV-10.5 (Marshall and Roy, 1990) and
cEHDV-1.5, kindly provided by P. Roy (IVEM. Oxford. UK),
ere used to express BTV-10 VP5 and EHDV-1 VP5,
espectively.
E. coli strains DH5 and XL1-Blue were used for cloning
f target DNA into pET vectors (Studier et al., 1990). E.
oli strains BL21(DE3)pLysS and BL21(DE3)pLysE (Grod-
erg and Dunn, 1988) were used as the host for expres-
ion. E. coli strain GM119, lacking the dam methylase,
as used to prepare nonmethylated plasmid DNA for
ubsequent digestion by restriction enzyme ClaI.
roduction of MAbs
Production and selection of hybridoma lines using
urified AHSV as antigen were performed following the
rocedure previously described (Sanz et al., 1985). The
ulture medium of hybridomas was screened for reactiv-
ty with AHSV by ELISA. The protein specificities of
LISA-positive clones were determined by immunopre-
ipitation and immunoblotting (Ranz et al., 1992). VP5-
ositive hybridomas were cloned four times by limiting
ilution and purified from ascitic fluid by HPLC (Beck-
an). The isotype of the MAbs was determined by ELISA,
sing specific anti-mouse subtype antisera (Sigma).
onstruction of E. coli expression vectors
The complete AHSV-4 VP5 coding sequence was ob-
ained from the recombinant plasmid pAcYM1.AHSV-4.6
Martı´nez-Torrecuadrada et al., 1994). The constructs
sed in this study are shown in Fig. 1. The following VP5
ragments were generated by using convenient restric-
ion enzymes sites: VP5 gene, A (nt 1–1038, BamHI frag-
ent, nt 1 is the first nucleotide (G) of the segment M6);
(nt 1039–1564, BamHI fragment); C (nt 470–1038, SnaBI
o BamHI); D (nt 1–162, BamHI to ClaI); E (nt 163–469,
laI to SnaBI); F (nt 470–809, SnaBI to HindIII); G (nt
10–1038, HindIII to BamHI); H (nt 470–615, SnaBI to
luI); I (nt 616–809, MluI to HindIII); N (nt 78–269, AhaII
ragment); O (nt 270–469, AhaII to SnaBI). Fragments with
amHI ends were directly ligated with BamHI-digested
hosphatase-treated pET3 or pET3x (Studier et al., 1990).
ET3x vectors were chosen to express fragments
maller than 350 bp. Fragments with BamHI-incompati-
le ends were first subcloned into pMTL plasmids to
enerate BamHI-compatible ends and subsequently
loned into pET expression vectors.
If appropriate enzymes sites were not available,
P5 fragments were synthesized by PCR with Vent
NA polymerase (Biolabs). The samples were sub-
ected to 25 cycles of denaturation at 94°C for 1 min,
rimer annealing at 50°C for 1 min, and extension
t 72°C for 1.5 min. The oligonucleotides used wereP5.1, 59-CATAGATCTCGGCGCCAGACCCGTTGAGC-39;
P5.2, 59-AAAGGATCCTTCTATTTTCGCATTGTGTG-39;
P5.3, 59-GCGAGATCTGAAAAATTTGGTAAAGATTTAT-39;
P5.4, 59-CTAGGATCCGTACTTAATTTCGTTACCTTCC-39;
P5.5, 59-ATGGGATCCGTAGCAAAAGCGCTTACC-39;
P5.6, 59-TTGAGATCTGCGATATAGCTTTGTAATG-39;
P5.7, 59-CTAAGATCTCGCGCGTTACAAACAGAGGA-
GATTTG-39; VP5.8, 59-CTAGGATCCTCTAGTCTCATCTC-
TGTGCGCAAATCTTC-39; and VP5.9, 59-TTCGGATCC-
GCGTCAAATTTCTCTCTAT-39 (restriction sites are un-
erlined). The VP5 fragments generated by PCR were the
ollowing: J (nt 539–586 from primer VP5.7 to VP5.8), K (nt
70–541 from primer VP5.5 to VP5.6), L (nt 470–586 from
rimer VP5.5 to VP5.8), M (nt 539–619 from primer VP5.7
o VP5.9), P (nt 266–379 from primer VP5.1 to VP5.2),
nd Q (nt 380–469 from VP5.3 to VP5.4). The resulting
CR products were digested with BamHI or BglII and
ere cloned directly into BamHI-digested and dephos-
horylated pET3x.
After transformation of E. coli DH5 competent cells,
ositive clones were selected by extensive restriction
nalysis of plasmid. The orientation of the inserts and the
unction sequences of the recombinant plasmids were
equenced by the dideoxynucleotide method, using
rimers 59-CTTTAAGAAGGAGATATAC-39 for pET3- and
9-CTATCCGCAACGTTATGGGC-39 for pET3x-derived plas-
ids. Strain BL21(DE3)pLysS or BL21(DE3)pLysE compe-
ent cells were transformed with each of the recombinant
lasmids and positive colonies were selected by their
esistance to ampicillin and chloramphenicol.
nduction, purification, and analysis of E. coli-derived
usion proteins
Single colonies of BL21(DE3)pLysS or BL21(DE3)pLysE
ontaining the indicated plasmid were grown and in-
uced with 0.4 mM IPTG (Boehringer Mannheim) as
escribed (Martinez-Torrecuadrada and Casal, 1995). Af-
er 3 h, the induced bacteria were centrifuged for 5 min
t 10,000 rpm and dissolved in loading buffer (10 mM
ris–HCl, pH 6.9, 10% SDS, 10% b-mercaptoethanol,
.02% bromophenol blue, 25% glycerol). The mixture was
oiled for 5 min and electrophoresed in a 7–15% SDS–
olyacrylamide gradient gel. Visualization of proteins
as carried out by staining with Coomassie brilliant blue.
Inclusion bodies containing the VP5-fragment fusion
roteins were purified by guanidinium chloride solubili-
ation as described previously (Martı´nez-Torrecuadrada
nd Casal, 1995).
mmunoblotting analyses
After SDS–PAGE, proteins were transferred electro-
horetically onto a Hybond-C membrane (Amersham,
K) and blocked with 3% skimmed milk in PBS contain-
ng 0.05% Tween 20 for 1 h at room temperature. After
locking, filters were incubated with either rabbit sera at
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458 MARTI´NEZ-TORRECUADRADA ET AL.1:100 dilution, horse sera at a 1:50 dilution, or purified
Ab IgG at 10 mg/ml in blocking buffer for 2 h at room
emperature and washed several times with 0.05%
ween 20 in PBS. Bound antibody was detected with a
/2000 dilution of alkaline phosphatase-conjugated pro-
ein A (Sigma), peroxidase-conjugated protein G (Pierce,
ockford, IL), or phosphatase-conjugated anti-mouse
gG (Sigma), respectively. Finally, membranes were de-
eloped with 4-chloro-naphthol and hydrogen peroxide
n PBS for the detection of peroxidase activity or with
itroblue tetrazolium chloride (Gibco BRL) and bromo-
hloroindoyl phosphate (Pierce) as substrates for detec-
ion of phosphatase activity.
mmunization of animals
Groups of five 3-week-old BALB/c mice were primed
ntraperitoneally with about 50 mg of the corresponding
usion protein, which was semipurified as described
bove and emulsified with an equal volume of Freund’s
omplete adjuvant (Sigma). Two further injections, by the
ame route and with the same dose of antigen in
reund’s incomplete adjuvant (Sigma), were given after 2
nd 6 weeks. Each group of mice was bled and antisera
ere collected 10 days after the final injection.
Female New Zealand White rabbits were immunized
ith baculovirus-expressed VP5. AcAHSV-4.5-infected
nsect cells were harvested at 72 h postinfection by
entrifugation at 200 g for 10 min, washed once with PBS,
nd resuspended in PBS at a density of 5–7 3 107
ells/ml. An aliquot was analyzed by SDS–PAGE and
oomassie blue staining to estimate the amounts of
ecombinant VP5 present. A total of 2 3 107 infected
ells, containing about 50 mg of VP5, were injected
ntramuscularly using Alhydrogel (Superfos, Denmark)
ogether with 100 mg of Quil A (Superfos) as adjuvants.
abbits were boosted twice at 4-week intervals, first with
djuvant and then without adjuvant. Blood samples were
aken for serological assays 10 days after the final im-
unization. Another group of female New Zealand White
abbits were immunized with purified recombinant VP2
nd VP5 as described previously (Martı´nez-Torrec-
adrada et al., 1994).
Polyclonal anti-AHSV-4 sera were obtained from in-
ected horses or from horses vaccinated with inactivated
accine (Martı´nez-Torrecuadrada et al., 1994).
LISAs
An indirect ELISA was used to detect AHSV-specific
ntibodies. Briefly, microtiter plates (Nunc, Roskilde,
enmark) were coated overnight at 4°C with 0.5 mg/well
f CsCl gradient-purified AHSV-4 in 0.1 M carbonate
uffer, pH 9.6. Plates were washed and serial fivefold
ilutions of rabbit or mouse sera in blocking buffer (0.35
NaCl, 0.05% Tween 20 in PBS) were then added. After
1-h incubation at 37°C, plates were washed and toach well was added a 1/2000 dilution of peroxidase-
onjugated anti-mouse (Sigma) or anti-rabbit IgG (Sigma)
n blocking buffer and incubated 1 h at 37°C. Plates were
ashed again and bound enzyme was detected by add-
ng ABTS (2,29-azinobis(3-ethylbenzothiazoline-sulfonic
cid)) (Sigma) as substrate. The reaction was stopped
fter 10 min with the addition of 2% SDS and the absor-
ance was measured at 405 nm using an ELISA reader.
Identification of MAb-defined antigenic sites on AHSV-4
P5 was carried out by using a competitive binding
LISA as described previously (Ranz et al., 1992) with the
urified virus as antigen source.
n vitro neutralization assays
To assess the AHSV-4 neutralization capability of an-
ibodies, a PFU reduction test, 50 ml of seed virus, con-
aining about 105 PFU, were mixed with an equal volume
f each ascitic fluid and incubated for 2 h at 37°C. Serial
enfold dilutions were made with the virus–antibody mix-
ures and were added to 4 3 104 Vero cells. Virus
dsorption was allowed to proceed at 37°C for 2 h. The
edium was discarded and cells were covered with agar
verlay medium (DMEM containing 1% agarose and 2%
CS). After 7 days at 37°C, cell monolayers were fixed
ith 20% formaldehyde in PBS and stained with 1.5%
rystal violet in 50% ethanol. Plaques were counted in
ach well. Virus neutralization activity was expressed as
he percentage of plaque reduction. Ascitic fluid of neu-
ralizing AHSV-4 VP2-specific and rabbit hemorrhagic
isease virus-specific MAb were included as positive
nd negative controls, respectively.
Vero monolayer protection assay was performed as
escribed previously (Martı´nez-Torrecuadrada and Casal,
995). End-point titration was determined as the recipro-
al value of the highest serum dilution that causes 50%
eduction of cell monolayer.
EPSCAN
The complete set of 494 overlapping 12-mer peptides
ith sequences based on that of AHSV-4 VP5 (Iwata et
l., 1992) was synthesized onto polyethylene according
o established procedures and tested for binding by
ntibody in an ELISA test as described (Geysen et al.,
984). The criterium for assigning a site as antigenic was
aken as follows: the absorbance value should be at
east twice the background and there should be two or
ore neighboring peptides that reach this value. The
ackground was taken as twice the average absorbance
alue of 20 consecutive low-reacting peptides for which
he CV (coefficient of variation 5 SD/average 3 100) is
elow 20% of the average value.
The accessibility of the antigenic sequences in AHSV
as studied by preabsorbing antisera with sucrose gra-
ient purified AHSV-4 or as a negative control Aujezsky
isease virus similarly as previously described (Lange-
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459ANTIGENIC STRUCTURE OF AHSV-4 VP5eld et al., 1993). The percentage of blocking is calcu-
ated from the absorbance values obtained for a site
after substracting the background value) according to
he formula (1 2 (EA405nmC 2 EA405nmAHSV)/EA405nmC)
100%, where EA405nmC is the sum of absorbance
alues in control sample and EA405nmAHSV is the sum of
bsorbance values in AHSV-4 preabsorbed sample.
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